Highbridge Capital Management’s Pacira BioSciences PCRX Stock Holding History

Highbridge Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50,000	Closed	-$1.56M	–	1231
2018 Q1	$1.56M	Sell	50,000 -100,000	-67%	-$3.56M	0.03%	466
2017 Q4	$6.85M	Sell	150,000 -52,700	-26%	-$2.09M	0.12%	213
2017 Q3	$7.61M	Buy	202,700 +8,618	+4%	+$347K	0.11%	208
2017 Q2	$9.26M	Buy	194,082 +114,082	+143%	+$5.29M	0.14%	184
2017 Q1	$3.65M	Buy	+80,000	New	+$3.46M	0.05%	347
2016 Q4	–	Sell	-55,872	Closed	-$1.91M	–	1514
2016 Q3	$1.91M	Buy	+55,872	New	+$2.19M	0.03%	439
2015 Q4	–	Sell	-35,691	Closed	-$1.47M	–	1724
2015 Q3	$1.47M	Buy	+35,691	New	+$2.19M	0.02%	647

Other funds holding PCRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Highbridge Capital Management's PCRX Position: Q2 2018 in Review

Highbridge Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2018, closing a stake of 50,000 shares — an estimated $1.56M sold.

Highbridge Capital Management first reported a position in PCRX in Q3 2015 and held it in 7 quarters. The position peaked at $9.26M in Q2 2017. 156 funds tracked by Wall St. Rank hold PCRX as of Q2 2018.

Highbridge Capital Management reported no remaining Pacira BioSciences position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 50,000 Pacira BioSciences shares in Q2 2018, an estimated $1.56M.
Highbridge Capital Management first reported a position in Pacira BioSciences in Q3 2015 and held it in 7 quarters.
Highbridge Capital Management's Pacira BioSciences position peaked at $9.26M in Q2 2017.
156 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.